Total reported value
$1.2B
Reporting period: 2026-03-31 · Number of holdings: 46
Vivo Capital, LLC disclosed 46 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $1.2B and a quarterly turnover rate of 79.8%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "V"
Add ERAS
+31.0% $162.1M
Trim 430
-75.0% -$145.7M
Trim COGT
-82.4% -$69.0M
Add PRAX
+3.0% $12.3M
Add TNGX
0.0% $26.0M
Add CRVS
+25.6% $23.8M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ERAS | Erasca INC | Stock-Other | 16.34% | +14.11% | +31.04% | |
| 2 | PRAX | Praxis Precision Medicines I | Stock-Other | 9.08% | +2.81% | +3.04% | |
| 3 | 430 | Terns Pharmaceuticals INC | Stock-Other | 5.85% | -8.11% | -75.04% | |
| 4 | TRVI | Trevi Therapeutics INC | Stock-Other | 5.05% | +0.93% | — | |
| 5 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 4.63% | +1.58% | +8.37% | |
| 6 | CMPX | Compass Therapeutics INC | Stock-Other | 4.20% | — | — | |
| 7 | TNGX | Tango Therapeutics INC | Stock-Other | 3.75% | +2.52% | — | |
| 8 | SABS | Sab Biotherapeutics INC | Stock-Other | 3.64% | +0.88% | — | |
| 9 | CRVS | Corvus Pharmaceuticals INC | Stock-Other | 3.41% | +2.30% | +25.56% | |
| 10 | DRUG | Bright Minds Biosciences INC | Stock-Other | 3.38% | +0.85% | +11.08% | |
| 11 | SVA | Sinovac Biotech Ltd. | Stock-Other | 3.17% | — | — | |
| 12 | DNTH | Dianthus Therapeutics INC | Stock-Other | 2.47% | +1.53% | — | |
| 13 | DYN | Dyne Therapeutics INC | Stock-Other | 2.35% | -0.96% | -40.44% | |
| 14 | ABVX | Abivax Sa-adr | Stock-Other | 2.22% | -0.91% | -33.33% | |
| 15 | NERV | Minerva Neurosciences INC | Stock-Other | 2.17% | +1.04% | — | |
| 16 | ACRS | Aclaris Therapeutics INC | Stock-Other | 2.08% | +0.35% | -25.00% | |
| 17 | ORIC | Oric Pharmaceuticals INC | Stock-Other | 1.95% | +0.83% | -12.73% | |
| 18 | ANRO | Alto Neuroscience INC | Stock-Other | 1.94% | +0.75% | — | |
| 19 | FTH | Faeth Therapeutics INC | Stock-Other | 1.89% | +1.89% | NEW | |
| 20 | AVBP | Arrivent Biopharma INC | Stock-Other | 1.70% | +1.70% | NEW | |
| 21 | LBRX | Lb Pharmaceuticals INC | Stock-Other | 1.64% | +0.49% | — | |
| 22 | MANE | Veradermics INC | Stock-Other | 1.57% | +1.57% | NEW | |
| 23 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 1.56% | -0.12% | — | |
| 24 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.55% | +0.70% | — | |
| 25 | DSGN | Design Therapeutics INC | Stock-Other | 1.43% | +0.45% | — | |
| 26 | COGT | Cogent Biosciences INC | Stock-Other | 1.35% | -4.16% | -82.40% | |
| 27 | GERN | Geron CORP | Stock-Other | 1.07% | -1.25% | -68.15% | |
| 28 | UNCY | Unicycive Therapeutics INC | Stock-Other | 0.98% | +0.31% | — | |
| 29 | ANTX | An2 Therapeutics INC | Stock-Other | 0.90% | +0.90% | NEW | |
| 30 | OLMA | Olema Pharmaceuticals INC | Stock-Other | 0.83% | -0.26% | — | |
| 31 | SLNOEUR | Soleno Therapeutics INC | Stock-Other | 0.82% | -1.86% | -67.05% | |
| 32 | EPRX | Eupraxia Pharmaceuticals INC | Stock-Other | 0.81% | — | — | |
| 33 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.66% | +0.66% | NEW | |
| 34 | SRZN | Surrozen INC | Stock-Other | 0.63% | +0.25% | — | |
| 35 | ALXO | Alx Oncology Holdings INC | Stock-Other | 0.53% | +0.53% | NEW | |
| 36 | MNPR | Monopar Therapeutics INC | Stock-Other | 0.41% | +0.03% | — | |
| 37 | MSLE | Satellos Bioscience INC | Stock-Other | 0.38% | +0.38% | NEW | |
| 38 | PEPG | Pepgen INC | Stock-Other | 0.34% | -0.64% | — | |
| 39 | SERA | Sera Prognostics Inc-a | Stock-Other | 0.28% | -0.03% | — | |
| 40 | TENX | Tenax Therapeutics INC | Stock-Other | 0.28% | +0.12% | — | |
| 41 | VRDN | Viridian Therapeutics INC | Stock-Other | 0.27% | -1.71% | -83.08% | |
| 42 | TIL | Instil Bio INC | Stock-Other | 0.20% | -0.01% | — | |
| 43 | KTTA | Pasithea Therapeutics CORP | Stock-Other | 0.13% | -0.05% | — | |
| 44 | CMPS | Compass Pathways PLC | Stock-Other | 0.09% | +0.09% | NEW | |
| 45 | BOLT | Bolt Biotherapeutics INC | Stock-Other | 0.02% | — | — | |
| 46 | DTIL | Precision Biosciences INC | Stock-Other | — | — | — |
Performance for Q3 2026
+10%
Performance Last 4 Quarters
+10%
Based on 2 months of available history
Based on 71% of reported portfolio value with available pricing
Not enough sector-mapped data yet
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 46 | $1.2B | 80 | |
| 2025-12-31 | 47 | $1.5B | 78 | |
| 2025-09-30 | 47 | $1.2B | 83 | |
| 2025-06-30 | 42 | $977.1M | 0 | |
| 2025-03-31 | 40 | $755.1M | 100 | |
| 2024-12-31 | 40 | $892.6M | 0 | |
| 2024-09-30 | 43 | $1.2B | 0 | |
| 2024-06-30 | 42 | $1.1B | 0 | |
| 2024-03-31 | 42 | $1.3B | 0 | |
| 2023-12-31 | 47 | $1.2B | 0 | |
| 2023-09-30 | 53 | $912.8M | 0 | |
| 2023-06-30 | 48 | $1.4B | 0 | |
| 2023-03-31 | 48 | $1.4B | 0 | |
| 2022-12-31 | 48 | $868.5M | 0 | |
| 2022-09-30 | 51 | $905.8M | 0 | |
| 2022-06-30 | 49 | $995.9M | 0 | |
| 2022-03-31 | 54 | $1.5B | 0 | |
| 2021-12-31 | 55 | $1.7B | 0 | |
| 2021-09-30 | 60 | $2.2B | 0 | |
| 2021-06-30 | 59 | $2.3B | 27 | |
| 2021-03-31 | 63 | $2.8B | 52 | |
| 2020-12-31 | 59 | $2.2B | 51 | |
| 2020-09-30 | 64 | $1.7B | 49 | |
| 2020-06-30 | 54 | $1.4B | 58 | |
| 2020-03-31 | 53 | $1.1B | 100 | |
| 2019-12-31 | 49 | $1.4B | 44 | 1000Com20000003000000 |
| 2019-09-30 | 49 | $878.8M | 100 | 1000Com20000003000000 |
| 2019-06-30 | 46 | $1.1B | 37 | |
| 2019-03-31 | 49 | $1.0B | 48 | |
| 2018-12-31 | 45 | $783.1M | 34 | |
| 2018-09-30 | 44 | $992.2M | 48 | |
| 2018-06-30 | 40 | $776.1M | 57 | |
| 2018-03-31 | 34 | $705.9M | 66 | |
| 2017-12-31 | 30 | $466.9M | 39 | |
| 2017-09-30 | 29 | $494.8M | 78 | |
| 2017-06-30 | 26 | $397.1M | 39 | |
| 2017-03-31 | 23 | $339.9M | 33 | |
| 2016-12-31 | 25 | $303.5M | 23 | |
| 2016-09-30 | 22 | $320.9M | 56 | |
| 2016-06-30 | 23 | $366.2M | 31 | |
| 2016-03-31 | 24 | $398.7M | 0 |
Vivo Capital, LLC's most significant position changes for 2026-03-31: Sold out: Cidara Therapeutics INC (CDTX); Sold out: Avadel Pharmaceu; Sold out: Zenas Biopharma INC (ZBIO); New buy: Faeth Therapeutics INC (FTH); New buy: Arrivent Biopharma INC (AVBP).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ERAS | Erasca INC | +14.1% | +31.04% | Add |
| 2 | PRAX | Praxis Precision Medicines I | +2.8% | +3.04% | Add |
| 3 | TNGX | Tango Therapeutics INC | +2.5% | — | Unchanged |
| 4 | CRVS | Corvus Pharmaceuticals INC | +2.3% | +25.56% | Add |
| 5 | DBVT | Dbv Technologies Sa-spon Adr | +1.6% | +8.37% | Add |
| 6 | DNTH | Dianthus Therapeutics INC | +1.5% | — | Unchanged |
| 7 | NERV | Minerva Neurosciences INC | +1% | — | Unchanged |
| 8 | TRVI | Trevi Therapeutics INC | +0.9% | — | Unchanged |
| 9 | SABS | Sab Biotherapeutics INC | +0.9% | — | Unchanged |
| 10 | DRUG | Bright Minds Biosciences INC | +0.9% | +11.08% | Add |
| 11 | ORIC | Oric Pharmaceuticals INC | +0.8% | -12.73% | Trim |
| 12 | ANRO | Alto Neuroscience INC | +0.8% | — | Unchanged |
| 13 | MLTX | Moonlake Immunotherapeutics | +0.7% | — | Unchanged |
| 14 | LBRX | Lb Pharmaceuticals INC | +0.5% | — | Unchanged |
| 15 | DSGN | Design Therapeutics INC | +0.5% | — | Unchanged |
| 16 | ACRS | Aclaris Therapeutics INC | +0.4% | -25.00% | Trim |
| 17 | UNCY | Unicycive Therapeutics INC | +0.3% | — | Unchanged |
| 18 | SRZN | Surrozen INC | +0.3% | — | Unchanged |
| 19 | TENX | Tenax Therapeutics INC | +0.1% | — | Unchanged |
| 20 | MNPR | Monopar Therapeutics INC | 0% | — | Unchanged |
| 21 | TIL | Instil Bio INC | 0% | — | Unchanged |
| 22 | SERA | Sera Prognostics Inc-a | 0% | — | Unchanged |
| 23 | KTTA | Pasithea Therapeutics CORP | -0.1% | — | Unchanged |
| 24 | CAMP | Camp4 Therapeutics CORP | -0.1% | — | Unchanged |
| 25 | OLMA | Olema Pharmaceuticals INC | -0.3% | — | Unchanged |
| 26 | PEPG | Pepgen INC | -0.6% | — | Unchanged |
| 27 | ABVX | Abivax Sa-adr | -0.9% | -33.33% | Trim |
| 28 | DYN | Dyne Therapeutics INC | -1% | -40.44% | Trim |
| 29 | GERN | Geron CORP | -1.3% | -68.15% | Trim |
| 30 | VRDN | Viridian Therapeutics INC | -1.7% | -83.08% | Trim |
| 31 | SLNOEUR | Soleno Therapeutics INC | -1.9% | -67.05% | Trim |
| 32 | COGT | Cogent Biosciences INC | -4.2% | -82.40% | Trim |
| 33 | 430 | Terns Pharmaceuticals INC | -8.1% | -75.04% | Trim |
| 34 | CDTX | Cidara Therapeutics INC | — | EXIT | Sold out |
| 35 | ✓ | Avadel Pharmaceu | — | EXIT | Sold out |
| 36 | ZBIO | Zenas Biopharma INC | — | EXIT | Sold out |
| 37 | FTH | Faeth Therapeutics INC | — | NEW | New buy |
| 38 | AVBP | Arrivent Biopharma INC | — | NEW | New buy |
| 39 | MANE | Veradermics INC | — | NEW | New buy |
| 40 | CTMX | Cytomx Therapeutics INC | — | EXIT | Sold out |
| 41 | ANTX | An2 Therapeutics INC | — | NEW | New buy |
| 42 | ABEO | Abeona Therapeutics INC | — | EXIT | Sold out |
| 43 | VSTM | Verastem INC | — | EXIT | Sold out |
| 44 | OKUR | Onkure Therapeutics Inc-a | — | NEW | New buy |
| 45 | SLN | Silence Therapeutics Plc-adr | — | EXIT | Sold out |
| 46 | ALXO | Alx Oncology Holdings INC | — | NEW | New buy |
| 47 | PALI | Palisade Bio INC | — | EXIT | Sold out |
| 48 | MSLE | Satellos Bioscience INC | — | NEW | New buy |
| 49 | CMPS | Compass Pathways PLC | — | NEW | New buy |
| 50 | ✓ | Engene Holdings INC | — | EXIT | Sold out |
Institutions with a similar AUM
CIK 0001537621
Total reported value
$1.2B
555 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001589176
Total reported value
$1.2B
82 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001008877
Total reported value
$1.2B
163 stks
2026-06-30
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001792126
Total reported value
$2.0B
66 stks
2026-03-31
3 of the top 5 holdings overlap, including Erasca INC
CIK 0001582844
Total reported value
$141.8M
27 stks
2026-03-31
2 of the top 5 holdings overlap, including Praxis Precision Medicines I
CIK 0001583977
Total reported value
$2.0B
47 stks
2026-03-31
2 of the top 5 holdings overlap, including Praxis Precision Medicines I